Richard Pavelock
Addiction Medicine · Statesville, NCNPI 1487739579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $873 and has fallen 97.7% since, to $20 in 2025.
Across 78 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$325
- Otsuka America Pharmaceutical, Inc.$215
- Neurocrine Biosciences, Inc.$153
- AbbVie$120
- Teva Pharmaceuticals USA, Inc.$94
- Ironshore Pharmaceuticals Inc.$79
- plus $428 from 15 others
What the payments were for
- Food & beverage$1,413100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,413 in reported general payments places this provider in the 75th percentile of 42 addiction medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $16,988 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 207 | $14,389 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 53 | $12,450 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 28 | $6,911 |
| Carbamazepine ErCarbamazepine | 28 | $3,500 |
| Gabapentin | 55 | $793 |
| Buprenorphine Hcl | 27 | $575 |
| Vilazodone Hcl | 11 | $454 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $447 |
| Promethazine Hcl | 19 | $407 |
| Potassium Chloride | 14 | $335 |
| Celecoxib | 26 | $294 |
| Topiramate | 32 | $289 |
| Risperidone | 12 | $202 |
| ValacyclovirValacyclovir Hcl | 13 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $215 | $16,98812 claims |
| Indivior Inc.Suboxone | $25 | $12,45053 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 42 addiction medicine providers in North Carolina.
Other addiction medicine in Statesville
- Bernard GottschalkWilmington$188K
- Hien NguyenApex$145K
- Gary LeonhardtGreenville$92K
- Emily Rayes-PrinceMonroe$69K
- Jonathan HallHendersonville$8K
- Barry WilliamsWinston-Salem$4K
- Johnny WilliamsGreenville$3K
- Heather ManosCharlotte$3K
- Sara KoenigCary$2K
- Gail GriffinCharlotte$655
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.